Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
| Company | Change | P/E (TTM) |
|---|---|---|
GSKGlaxoSmithKline PLC ADR | +0.31% | 111.08 |
NVSNovartis AG ADR | +2.79% | 28.18 |
ABTAbbott Laboratories | -0.03% | 23.37 |
BMYBristol-Myers Squibb Co. | -0.93% | 72.24 |
JNJJohnson & Johnson | -0.30% | 20.43 |
LLYEli Lilly & Co. | +0.01% | 34.72 |
PFEPfizer Inc. | +0.15% | 24.96 |
RHHVFRoche Holding AG Part. Cert. | +1.02% | 23.19 |
SNYSanofi ADR | -0.94% | 22.02 |
TEVATeva Pharmaceutical Industries Ltd. ADR | -0.43% | 25.73 |
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. It is a global research-driven pharmaceutical company that discovers, develops, manufactures and...
| Q2 2016 Estimate Trends | |
|---|---|
| Current: | $0.91 |
| 1 month ago: | $0.91 |
| 3 months ago: | $0.90 |
| Q3 2016 Estimate Trends | |
|---|---|
| Current: | $0.98 |
| 1 month ago: | $0.98 |
| 3 months ago: | $0.98 |
| Mar 2016 | 5-quarter trend | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth | +18.05% | | ||||||||
| Sales or Revenue | 9.17 B | | ||||||||
| Sales or Revenue Growth | -0.95% | | ||||||||
| EBITDA | +3.58 B | | ||||||||
| 2015 | 5-year trend | |||||||||
| Net Income Growth | -62.73% | | ||||||||
| Sales or Revenue | 38.77 B | | ||||||||
| Sales or Revenue Growth | -7.92% | | ||||||||
| EBITDA | +13.78 B | |